Roche publishes PhI data for KRAS drug in NEJM paper as it chases Amgen, Mirati

On a quest not just to catch up with, but leapfrog, Amgen and Mirati in the KRAS race, Roche has released early monotherapy data on its in-house candidate across a variety of cancers.

Roche, which presented some divarasib data at the AACR conference in April, spelled out the most comprehensive…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks